

RESEARCH ARTICLE

Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland

Beat Müllhaupt^{1*}, Philip Bruggmann², Florian Bihl³, Sarah Blach⁴, Daniel Lavanchy⁵, Homie Razavi⁴, David Semela⁶, Francesco Negro⁷

1 Swiss HPB (Hepato-Pancreato-Biliary) Center and Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland, **2** Arud Centres for Addiction Medicine, Zürich, Switzerland, **3** Gastroenterology Department, Ospedale Cantonale, Bellinzona, Switzerland, **4** Center for Disease Analysis (CDA), Louisville, Colorado, United States of America, **5** Consultant, Ruelle des Chataigniers 1, CH-1026 Denges VD, Switzerland, **6** Division of Gastroenterology & Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, **7** Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Genève, Switzerland

* beat.muellhaupt@usz.ch



CrossMark
click for updates

OPEN ACCESS

Citation: Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, et al. (2015) Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS ONE 10(6): e0125214. doi:10.1371/journal.pone.0125214

Academic Editor: Chen-Hua Liu, National Taiwan University Hospital, TAIWAN

Received: December 2, 2014

Accepted: March 22, 2015

Published: June 24, 2015

Copyright: © 2015 Müllhaupt et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its supporting information files.

Funding: This project was supported by Gilead Sciences. Gilead Sciences had no input on the content, the study design, data selection, decision to publish, or preparation of the manuscript.

Competing Interests: Beat Müllhaupt has served as an advisory board member for Roche, MSD, Janssen Therapeutics, AbbVie, Boehringer Ingelheim, Gilead and BMS; as a consultant for Gilead and AbbVie; and has received research grants from Roche and Gilead. Philip Bruggmann has served as advisor and speaker

Abstract

Background

Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment to reduce HCC and mortality. Furthermore, the costs associated with untreated HCV were modeled.

Methods

Hepatitis C disease progression and mortality were modeled. Baseline historical assumptions were collected from the literature and expert interviews and strategies were developed to show the impact of different levels of intervention (improved drug cure rates, treatment and diagnosis) until 2030.

Results

Under the historical standard of care, the number of advanced stage cases was projected to increase until 2030, at which point the annual economic burden of untreated viremic infections was projected to reach €96.8 (95% Uncertainty Interval: €36 – €232) million. Scenarios to reduce HCV liver-related mortality by 90% by 2030 required treatment of 4,190 \geq F2 or 3,200 \geq F3 patients annually by 2018 using antivirals with a 95% efficacy rate. Delaying the implementation of these scenarios by 2 or 5 years reduced the impact on mortality to 75% and 57%, respectively.

Conclusions

With today's treatment efficacy and uptake rates, hepatitis C disease burden is expected to increase through 2030. A substantial reduction in disease burden can be achieved by

for, and has received project and research grants from Roche, MSD, Janssen, AbbVie, Gilead, Viif and BMS. Sarah Blach and Homie Razavi are employees of the Center for Disease Analysis (CDA), Louisville, Colorado, USA. David Semela has served as a consultant for Gilead, an advisor for Roche, MSD, Gilead, Novartis, Janssen and Boehringer Ingelheim and has received an unrestricted research grant from Roche. Francesco Negro has served as advisor for MSD, Gilead, Novartis, Bristol Myers Squibb, AbbVie and Janssen and has received unrestricted research grants from Roche and Gilead. Florian Bihl and Daniel Lavanchy have no conflicts of interest to declare. As part of this project, none of the authors were part of any activities related to patents, product development or marketed products. The funding of this project by Gilead does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

means of both higher efficacy drugs and increased treatment uptake. However, these efforts cannot be undertaken without a simultaneous effort to diagnose more infections.

Introduction

The World Health Organization calls hepatitis C virus (HCV) a silent disease [1]. This is not only due to its symptomless clinical course, even when it has progressed to advanced liver disease, but also to the frequency with which it is overlooked and under-funded in the political sphere [2]. HCV infection takes a chronic course in about 80% of those infected, posing a substantial risk of progressing to cirrhosis and hepatocellular carcinoma (HCC) [3–5]. Although HCV incidence and prevalence are decreasing, morbidity and mortality will increase in the next years as complications of end stage liver disease occur mostly 20–30 year after infection putting a significant burden on the health care and economical system [6].

There is evidence that treatment leading to a sustained viral response (SVR) can reverse the effects of early stage fibrosis, and slow the progression of cirrhosis into decompensation or HCC [7,8]. Thus, prompt identification and management of cases is imperative for mitigation of the increasing burden of disease resulting from an aging population [9]. There is not currently a national screening strategy to identify HCV cases in Switzerland. However, the Federal Office of Public Health (FOPH) has collected and maintained a notification database for all positive tests for non-A, non-B hepatitis and HCV since 1988 [9,10]. The aim of this study is to expand on recent modeling efforts through novel scenario development to assist in the development of national strategies for HCV control. Additionally, the cost of untreated HCV was analyzed.

Methods

HCV disease progression model

A detailed description of the HCV disease progression model was described previously [11] and is provided in [S1 Fig](#) and [S1 Table](#). The model was populated and calibrated using Swiss specific assumptions ([S1 File](#), [S2 Table](#)) to forecast the future burden of HCV by stage of the disease. For consistency, the HCV population by sequelae in 2030 was used for comparison to the 2013 populations in the analyses below, unless noted otherwise.

Model Outcomes. Model outcomes included annual estimates of total viremic infections as well as viremic infections by disease sequelae (e.g. fibrosis, cirrhosis and HCC). Deaths attributable to background mortality and liver related mortality were also tracked annually. The forecasts were collected for each scenario described below.

Epidemiology of the HCV infected population. A thorough review of published literature and government reports was conducted to describe the total population and HCV prevalent population, and meetings with key opinion leaders and HCV experts in Switzerland were held to gain consensus surrounding the inputs. Some of the inputs summarized below have been described in more detail elsewhere [12].

Base (1.6%) and high (1.8%) estimates for anti-HCV prevalence were chosen from a modeling study completed in 1998 [13] with a low estimate of 0.8% [9]. The age and gender distribution of HCV infected individuals was estimated using notification data from the FOPH [14] and the genotype (G) distribution was available through the Swiss Hepatitis C Cohort Study [15]. The model only tracks viremic cases, and a viremic rate of 79.7% was chosen to adjust antibody estimates [16]. Applying the anti-HCV prevalence and viremic rate estimates to Swiss population data [17] indicates there were approximately 88,000 (45,400–102,000) viremic HCV infections in 1998.

Notification data and analysis from the FOPH suggest that 41,300 anti-HCV (32,900 viremic) infections were diagnosed as of 2013, with approximately 1,310 new anti-HCV (1,050 viremic) diagnoses occurring annually since 2011 [12,14].

The number of annual new cases was defined as the sum of acute infections progressing to chronicity plus chronic (viremic) infections entering Switzerland through immigration. The FOPH reports that 711 acute infections of HCV were declared from 2002–2011, or approximately 71 acute infections annually [18]. Since only 20–25% of acute infections are symptomatic [9] and an estimated 79.7% become chronic, there may have been as many as 283 new chronic infections occurring annually. Additionally, during 2002–2011, it was estimated that as many as 8,820 anti-HCV infections entered Switzerland through migration (immigrants minus emigrants) [19,20], or approximately 700 viremic infections annually, based on the assumption that only 79.7% of those anti-HCV+ are viremic [16]. Combined, these data suggest that up to 985 new viremic infections occur annually in Switzerland. The analysis assumed the number of new infections and re-infection will remain constant in the future.

Background mortality was estimated using the Human Mortality Database of the University of Berkeley and the mortality rates recorded by the Swiss Federal Statistics Office (FSO) [21,22]. Additionally, increased mortality among active injecting drug users (IDUs) was estimated using a standardized mortality ratio (SMR) of 5.5 for individuals between 15 and 44 years of age given the effective harm reduction programs in place in the Switzerland [23–25]. Although IDU was reported as a risk factor among 65% of all HCV infections, only 21% were estimated to be active users [26–29].

Healthcare cost data. For both in- and outpatients the costs generated in 2012 were obtained from the financial department at the University Hospital in Zürich. For each patient the fibrosis stage according to the Metavir staging system was obtained either from liver biopsy or estimated from Fibroscan reports. In case the fibrosis stage was obtained by either method and the results were not in agreement, the biopsy data was used. The records included a history of liver transplantation, HCC diagnosis or if the patient was being treated for the HCV infection. In addition, all in-patients hospitalized in 2012 with acute HCV (International Classification of Diseases (ICD) 10 code: B17.1) and/or chronic HCV (ICD 10 code: B18.2), and the respective Swiss Procedure Code (CHOP) codes were extracted from the hospital database. Liver transplant reimbursement costs were available through the hospital, so data obtained through in- and outpatient records were used solely to estimate the cost of subsequent years of care following a liver transplantation. The cost of antiviral therapy was excluded from this analysis. Although all costs were obtained from a single-center, a consensus was found within the group of experts that these are representative for Switzerland.

Previous liver transplant was noted in outpatient records, and was defined by an ICD 10 code of T864 (or subsets). HCC was defined as HCC in outpatient records, or an in-patient ICD 10 code of C220. Decompensated cirrhosis was defined as an in-patient ICD 10 code of R18, G92 or I85, in the absence of more advanced liver disease. Cirrhosis was defined as F4 in outpatient records or an in-patient ICD 10 code of K746, in the absence of more advanced liver disease. Fibrosis data was only available from outpatient records.

Healthcare cost analysis (excluding treatment). Healthcare costs were calculated by matching in-patient and outpatient records and calculating a total cost for each patient. Patients were allocated to the most severe disease stage diagnosed and average cost was calculated across the total number of patients in the stage (Table 1). Finally, the average annual cost for patients with fibrosis and compensated cirrhosis were adjusted as follows to account for the zero costs incurred by the undiagnosed population.

$$\text{Average annual cost} = \text{Annual cost} * \% \text{ Diagnosed}$$

Table 1. Estimated cost per patient per year (excluding the cost of antiviral therapy), by disease stage, in 2011 Euros.

Disease Stage	Base cost* (€)	Low Cost** (€)	High Cost*** (€)
Chronic HCV (F0)	104	21	643
F1	169	14	1,100
F2	381	71	1,681
F3	866	134	4,618
Compensated Cirrhosis	2,174	98	16,352
Decompensated Cirrhosis	16,457	4,223	30,117
Hepatocellular Carcinoma	13,567	1,983	58,246
Liver Transplant	100,174	87,796	239,110
Liver Transplant—Subseq. Yrs	15,473	193	171,851

(* Base costs were calculated as described above, ** Low costs represent the minimum cost associated with each stage, *** High costs represent the maximum cost associated with disease each stage).

doi:10.1371/journal.pone.0125214.t001

This approach ignored the healthcare costs associated with HCV related comorbidities if the patients were not diagnosed with HCV. At the time of this analysis, cost of the new therapies was not available and treatment cost was excluded.

Sensitivity analysis. The uncertainty in assumptions/inputs was captured as a range (S3 Table) using a Beta-PERT distribution. Crystal Ball, an Excel add-in by Oracle was used to run Monte Carlo simulations to determine the 95% uncertainty intervals and sensitivity analysis.

Scenario development

Under the base case scenario (current standard of care), an estimated 1,100 patients were treated annually in Switzerland [12,30]. The pool of patients eligible for treatment was determined by the number of diagnosed patients who were age and fibrosis stage eligible, with no contraindications to treatment and who were willing to accept treatment. It was assumed that all patients between 15–69 years of age who had a fibrosis score of F2 or higher on the Metavir scale were eligible for standard and triple therapy. The average SVR for this population was 61% for G1 and G4, and 70% for G2 and G3. Additionally, it was assumed that 40% of patients were either contraindicated or refused current therapies [31,32].

Scenarios were modeled with changes to SVR, medical eligibility, treatment uptake, diagnosis rates, treated patient segments and the timing of access to the new therapies.

1. Discontinuation of treatment—all therapies were discontinued in 2014 to assess the effect of current treatment standards.
2. Increased treatment uptake and efficacy to achieve 50% or 90% reduction in mortality—two scenarios were developed to achieve a 50% and 90% reduction in liver-related disease burden and mortality by 2030 treating \geq F2 patients using antivirals with a 95% efficacy rate. Additionally, scenarios were run where the fibrosis stage threshold for starting therapy was increased to \geq F3 or F4 (including decompensated cirrhosis and transplant), keeping constant the goal of 50% and 90% reductions in mortality
3. Impact of time and patient segment—the impact of time was assessed by delaying the \geq F2-90%-reduction scenario by 2 or 5 years. The impact of patient segment was assessed by restricting treatment to \geq F3 or F4 patients. For all of these scenarios, SVR increases, as well as the number of treated patients remained the same as in the \geq F2-90%-reduction scenario.

- 90% reduction ‘hybrid’ scenario—the \geq F2-90%-reduction was modified to initially restrict treatment to F4 patients beginning in 2014. Restrictions were relaxed in 2016 (to include \geq F3) and 2018 (to include \geq F2).

Results

Base Case

Peak viremic prevalence of chronic HCV infection was reached in 2003 at 88,600 (41,500–98,500) viremic infections, and by 2013 there were 82,700 (37,200–93,400) infections (Fig 1). Although prevalence was estimated to decline to 63,200 (25,900–71,800) viremic infections in 2030, assuming that all inputs and outputs remain stable over time (including treatment uptake and efficacy) the number of individuals with advanced liver disease increased. The number of compensated cirrhosis ($n = 12,700$), decompensated cirrhosis ($n = 1,790$) and HCC ($n = 745$) cases were forecasted to increase 50%, 57% and 84% as compared to the 2013 populations (Fig 2). Additionally, by 2030, liver related mortality was forecasted to increase 72% (from 380 deaths to 650 deaths) as the HCV population ages (Fig 2).

The 2013 annual healthcare cost of viremic HCV (excluding antiviral treatment costs) was estimated at €74 (€36 –€157) million. The annual cost was projected to peak in 2030 at €97 (€36 –€232) million (Fig 1). Under the base case, the cumulative healthcare costs for 2013–2030 were estimated at €1,581 (€620 –€4,053) million.

The results of the sensitivity analysis are shown in S2 Fig. The analysis showed that the uncertainty in the anti-HCV prevalence is the driver of uncertainty accounting for most of the observed variability.

Discontinuation of Treatment

In the absence of treatment, viremic prevalence was forecasted to decrease at a slower rate than under the base case, with 73,400 viremic cases in 2030. Additionally, by 2030, the numbers of individuals with compensated cirrhosis and decompensated cirrhosis were projected to




Fig 1. Total viremic cases (blue) and associated healthcare costs (red), by year, 1950–2050 (the upper and lower bounds represent 95% uncertainty intervals).

doi:10.1371/journal.pone.0125214.g001

increase to 16,485 and 2,280 cases, respectively. The number of individuals with HCC, caused by HCV infection, was projected to increase to 910 cases, a 22% increase over the base case. Under this scenario, liver related mortality was projected to increase from 380 deaths in 2013 to 800 deaths in 2030, a 23% increase over the base case (Fig 3a).

Discontinuing treatment was associated with a projected €190 million per year increase in net costs from 2013–2030 as compared with the base case (cumulative cost = €1,771 million). The increase in cost was a result of the progression to more advanced disease by those who would have been cured under the base scenario. In 2030, annual costs were projected to be 24% higher than under the base case.

Treatment uptake required to achieve 50% or 90% reduction in mortality

In order to attain 50% reduction in mortality while restricting access to \geq F2 patients, an increase in treatment of up to 2,550 patients annually by 2018, with 95% SVR therapies, would be required (Table 2, Fig 3b). This strategy increases the number of patients, with a 50% increase in the number of patients treated beginning in 2016 (1,640 total) and a 155% increase beginning in 2018 (2,550 total). The model was designed to provide a warning when an insufficient number of patients was available for treatment. In order for treatment to increase at this rate, improved screening and diagnosis (i.e. from 1,050 viremic diagnoses annually in 2013 to 2,370 viremic diagnoses annually in 2020) and the treatment of patients up to 74 years of age were necessary.





Fig 2. Change in disease burden, by year, 1950–2030 (the upper and lower bounds represent 95% uncertainty intervals).

doi:10.1371/journal.pone.0125214.g002



* 90% reduction of mortality could not be achieved treating $\geq F4$ patients only because the model ran out of patients. The maximum achievable reduction was 77%.

Fig 3. Exploratory scenario outputs, 2013–2030. (A) HCV-related liver-related deaths, by scenario; (B) Maximum number of patients treated annually to achieve 50% or 90% reduction, by METAVIR stage treated; (C) Impact of treatment restrictions (restriction to $\geq F3$ or $F4$) on a strategy to reduce liver-related mortality by 90%, and the annual number of patients treated before ‘running out of patients’; (D) Impact of 2-year and 5-year delays on a strategy to reduce liver-related mortality by 90%.

doi:10.1371/journal.pone.0125214.g003

Table 2. Maximum annual treatment and diagnosis required for 50% and 90% reductions in HCC/Mortality, by treated stage.

Scenario	Annual Treatment Max	Annual Treatment 2030	Cumulative Treatment 2013–2030	Annual Diagnosis Max	
Base		1,100	19,700	1,050	
50% Reduction	$\geq F2$	2,550	39,700	2,370	
	$\geq F3$	1,850	30,000	2,370	
	$F4$	1,095	19,700	3,580	
90% Reduction	$\geq F2$	4,190	1,430	58,000	5,370
	$\geq F3$	3,200	1,640	46,900	6,010
	$F4^*$	1,750	1,415	26,100	7,900
	Hybrid	4,190	1,495	57,955	5,370

* A 90% reduction in mortality could not be attained if treatment was restricted to the $F4$ population.

doi:10.1371/journal.pone.0125214.t002

To attain 90% reduction in mortality while limiting access to \geq F2 patients, an increase in treatment of up to 4,190 patients annually by 2018, with 95% SVR therapies, would be required (Table 2, Fig 3b). This strategy increases the number of patients gradually, with a 50% increase in the number of treated patients beginning in 2014 (1,640 total), 50% increase beginning in 2016 (2,460 total), and 70% increase beginning in 2019 (4,190 total). In order for treatment to increase at this rate, improved screening and diagnosis is necessary (from 1,050 viremic diagnoses annually in 2013 to 5,370 viremic diagnoses annually in 2020) and the treatment of patients up to 79 years of age is compulsory.

Restricting therapy access to \geq F3 or F4 patients decreased the treatment rate required to reach 50% or 90% reduction (Table 2, Fig 3b), however the number of viremic patients diagnosed annually had to be increased, as shown in Table 2, to have sufficient number of patients to treat. Furthermore, 90% reduction could not be attained if treatment was restricted to the F4 population.

Scenario analyses around the \geq F2-90% reduction scenario

Restricting treatment to \geq F3 patients resulted in a rapid initial decrease in liver-related mortality, however liver related deaths in 2030 were very similar to those under the \geq F2-90%-reduction scenario (\geq F3-70 deaths in 2030, \geq F2-65 deaths in 2030) (Fig 3c, Table 3). Treating 4,190 \geq F3 patients annually was only sustainable until 2020, after which time the model predicted that only 2,500–3,400 patients were available to treat annually. Since fewer patients were treated cumulatively, the number of viremic infections increased 35%, as compared with the \geq F2 scenario.

Restrict to F4—Restricting treatment to F4 patients resulted in a very rapid initial decrease in liver related deaths followed by a plateau (Fig 3c). By 2030, there were 165 liver related deaths annually, 154% more than under the \geq F2 scenario (65 cases as shown in Table 3). The viremic prevalence in 2030 was 57,500—a 95% increase from the \geq F2 scenario (29,400).

Table 3. Model outputs by scenario, and scenario analysis surrounding \geq F2, 90% reduction in HCC/Mortality scenario.

Model Outputs by Scenario		HCC		Mortality		Prevalence		Decomp Cirrhosis		Comp Cirrhosis	
		2013	2030	2013	2030	2013	2030	2013	2030	2013	2030
Base		405	745	380	650	82,700	63,200	1,140	1,790	8,520	12,700
Scenario		HCC		Mortality		Prevalence		Decomp Cirrhosis		Comp Cirrhosis	
		Peak (Year)	2030	Peak (Year)	2030	2030	Peak (Year)	2030	Peak (Year)	2030	
Modeled Scenarios	Discontinued Treatment	910 (2030)	910	800 (2030)	800	73,400	2,280 (2030)	2,280	16,480 (2030)	16,485	
	\geq F2, 50% Reduction in Mortality	485 (2020)	350	455 (2019)	320	42,600	1,280 (2017)	730	9,250 (2017)	4,990	
	\geq F2, 90% Reduction in Mortality	455 (2018)	70	435 (2018)	65	29,400	1,270 (2016)	110	8,820 (2015)	825	
	Hybrid, 90% Reduction in Mortality	420 (2015)	75	420 (2019)	70	29,500	1,230 (2015)	120	8,670 (2014)	895	
Scenario Analysis, Max 4,190 tx / yr	\geq F2, 90% Reduction										
	2- year delay	500 (2020)	100	470 (2020)	115	30,000	1,360 (2018)	170	9,450 (2017)	1,235	
	5-year delay	565 (2023)	230	525 (2019)	260	35,700	1,500 (2021)	450	10,420 (2020)	3,010	
	Treat \geq F3	440 (2017)	65	430 (2019)	70	40,000	1,260 (2016)	115	8,670 (2014)	1,140	
	Treat F4	420 (2015)	150	420 (2019)	165	57,500	1,230 (2015)	250	8,670 (2014)	3,880	

doi:10.1371/journal.pone.0125214.t003




Fig 4. Projected base and hybrid scenario results for cirrhosis, decompensated cirrhosis and HCC, 1950–2050.

doi:10.1371/journal.pone.0125214.g004

Delay by 2 years—Delaying the \geq F2-90%-reduction scenario’s implementation by two years resulted in a 77% increase in liver related mortality by 2030 (Fig 3d, Table 3).

Delay by 5 years—Delaying the implementation by five years resulted in a 300% increase in liver related mortality by 2030 (Fig 3d, Table 3).

Hybrid scenario to reduce mortality by 90%

The hybrid approach to reduce mortality by 90% resulted in both a rapid initial decrease in liver-related deaths and allowed for sustained treatment of 4,190 patients annually until 2028. Thus, the viremic prevalence in 2030 was similar to that of the \geq F2-90%-reduction scenario, with 29,500 cases (compared with 29,400) (Table 3). The impact of the hybrid approach on reductions in compensated and decompensated cirrhosis, as well as HCC can be seen in Fig 4.

Discussion

Despite a decrease in the rate of new infections in Switzerland, HCV poses a considerable public health threat caused by secondary liver related morbidity and mortality of those already infected. This is further complicated by the fact that less than 50% of the infected population is aware of their infection [9].

With today’s treatment efficacy and uptake rates, the number of cases of HCV induced cirrhosis, decompensated cirrhosis and HCC is expected to steadily increase until 2030. It is important to note, however, that prevention (of disease or mortality) is an intangible outcome and recognition of current efforts is worth acknowledging. The analysis in which treatment was discontinued showed a 23% increase in mortality compared with current treatment, suggesting the importance of, at minimum, maintaining the current standard of care to prevent increased morbidity and mortality.

A key insight of this analysis was identification of factors that drive a reduction in HCV morbidity, mortality and total infections. A reduction in end stage liver diseases (ESLD) and liver related deaths (LRD) is achievable by focusing treatment on patients with high fibrosis (\geq F3 or F4); however, a significant reduction in the total number of infections cannot be achieved unless treatment is expanded to patients in the early stages of fibrosis. The trade-off to achieve a

reduction in total infections is the requirement for a higher number of patients to be treated to achieve the same level of reduction in ESLD and LRD by 2030. A significant reduction in the total number of infection is not achievable under the current treatment paradigm.

If managing the drug costs while minimizing liver related deaths, is the primary goal, then focusing on patients with late stage of fibrosis would achieve a significant reduction in HCV morbidity and mortality while treating fewer patients. Once this population has been depleted, treatment can be expanded to patients with a lower fibrosis (\geq F2 before \geq F1 before \geq F0) as demonstrated by the hybrid strategy. This strategy ensures that the patients who need treatment most are given a priority while managing the treatment cost and the increased demand on the healthcare system.

However, the analysis also showed that focusing treatment exclusively on F4 patients was not as effective in reducing LRD. This is driven by three factors: only those who are diagnosed can be treated, not all individuals with fibrosis score of F4 are diagnosed and individuals who are F4 tend to be older. Aside from the fact that decompensated cirrhotics cannot be treated with any combination therapy containing interferon, individuals who are F4 and not diagnosed will continue to progress and age. Once they pass age of 74, the analysis considers them ineligible for treatment. These individuals are ineligible for treatment independent of their future diagnosis status. In addition, studies have shown that some cirrhotic patients will continue to progress to ESLD after achieving SVR [8]. Thus, some portion of the F4 patients who are diagnosed, treated, and achieve SVR will continue to progress. Treating patients after they are cirrhotic is less effective than preventing them from becoming cirrhotic. Expansion of treatment to \geq F3 captured these individuals while they were younger than 74 years old and prevented disease progression.

This highlights another important observation—the impact of treatment to prevent disease progression. As shown in Fig 3C, the \geq F3 strategy was more effective in reducing LRD after 2021 as compared to the F4 strategy. This was because patients who achieved SVR were prevented from progressing to cirrhosis and subsequently ESLD. Those F3 cases who are undiagnosed will still have a chance to be diagnosed when they reach F4 thus improving the odds of capturing and treating them before they reach ESLD.

A strategy to reduce HCV prevalence by 90% in Switzerland must involve treatment regardless of liver disease stage. This approach would require a significant expansion of the current treatment capacity, possibly through appropriately trained mid-level providers and/or primary care physicians [33], i.e. according to a task shifting strategy already effectively tested for HIV infection [34,35] and recently proposed for HCV [36]. Once well tolerated and easy to administer therapies become available, a test-and-treat approach (where an HCV diagnosis is followed by a treatment offer) may be possible. The availability of such simplified regimens, effective for all patients independently of their baseline and on-treatment features, may further raise the trend of treating HCV as an infectious disease.

Increased detection and diagnosis of viremic cases is a primary requirement for all strategies aiming to significantly impact HCV disease burden. Therefore, enhancing detection rates in Switzerland has high priority in order to control the HCV epidemic. Birth cohort screening among individuals born between 1945 and 1965 has proven effective in the United States (US) [37], and a similar approach could be considered for Switzerland. The Swiss HCV epidemic is younger than that of the US, with 70% of the viremic population born between 1950 and 1975. Screening programs targeting this population are estimated to have the greatest success in identifying new cases.

Given the higher SVR of the new therapies, delays in access lead to slower reductions in mortality, morbidity and total infections between 2013 and 2030 (Table 3). A 2 and 5 years delay in the \geq F2 strategies lead to 80% and 300% higher liver related deaths in years 2030.

There were a number of limitations in this study that impact the accuracy of our base projections. Sensitivity analysis identified prevalence as the largest driver of uncertainty in the Swiss model—accounting for 88% of the variability. A wide range around prevalence was purposefully chosen to account for the variability in currently cited estimates; however, this underscores the need for a reliable, population based survey. Though not captured in the sensitivity analysis, additional uncertainty surrounds the notification data. Mandatory reporting of HCV in Switzerland is based on a passive surveillance system and is therefore subject to underreporting. However, this underreporting is limited by the fact that all cases are laboratory confirmed and that many laboratories have automated routines to report positive cases. Additionally, many patients have been tested several times, which increases the likelihood of cases being reported. Finally, there is uncertainty surrounding the source of infection, as 40% of reports cited “unknown” or missing routes of transmission. Percent of transmission due to IDU and transfusion were therefore calculated only among cases with a known exposure.

Finally, the analysis focused on ESLD and mortality and the impact of treatment as prevention was not considered. The latter would result in a faster drop in the total number of HCV infections by reducing HCV transmission. The impact of treatment as prevention on ESLD and LRD would be minimal in the time frame considered (2013–2030) since new infected individuals will take time to progress to ESLD.

In order to improve detection and treatment of HCV, Switzerland needs to coordinate its efforts nationwide. While the strategies mentioned in this paper are contingent upon the availability of new potent therapies with higher cure rates and improved treatment experience, the current standard of care shows a reduction in disease burden as compared to the modeled effects of discontinuing all treatment. Further modeling analyses are needed to evaluate the cost effectiveness of these aforementioned strategies, including the cost of medication. The analysis presented here highlights the need to develop timely strategies to reduce the effects of chronic HCV disease in Switzerland.

Supporting Information

S1 Fig. The flow of the HCV disease progression model.

(TIF)

S2 Fig. Tornado diagram highlighting the key drivers for the 2013 viremic prevalence estimate, with percent of variation explained by each parameter.

(TIF)

S1 File. General Population Assumptions.

(DOCX)

S1 Table. HCV Disease Progression Rates.

(DOC)

S2 Table. Base HCV(+) population assumptions.

(DOC)

S3 Table. Parameters Included in Sensitivity and Uncertainty Analysis.

(DOC)

Acknowledgments

The authors gratefully acknowledge the Swiss Federal Office of Public Health for providing Swiss data and comments throughout the model validation process.

Author Contributions

Conceived and designed the experiments: BM PB FB SB DL HR DS FN. Performed the experiments: BM PB FB SB DL HR DS FN. Analyzed the data: BM PB FB SB DL HR DS FN. Contributed reagents/materials/analysis tools: BM PB FB SB DL HR DS FN. Wrote the paper: BM PB FB SB DL HR DS FN.

References

1. World Health Organization—Department of Immunization VaB (2006) State of the art of new vaccine research and development. Geneva, Switzerland. WHO/IVB/06. 01: 1–12.
2. Edlin BR (2011) Perspective: test and treat this silent killer. *Nature* 474: S18–S19. doi: [10.1038/474S18a](https://doi.org/10.1038/474S18a) PMID: [21697837](https://pubmed.ncbi.nlm.nih.gov/21697837/)
3. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. *Clin Microbiol Infect* 17: 107–115. doi: [10.1111/j.1469-0691.2010.03432.x](https://doi.org/10.1111/j.1469-0691.2010.03432.x) PMID: [21091831](https://pubmed.ncbi.nlm.nih.gov/21091831/)
4. Wong JB, McQuillan GM, McHutchison JG, Poynard T (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. *Am J Public Health* 90: 1562–1569. PMID: [11029989](https://pubmed.ncbi.nlm.nih.gov/11029989/)
5. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD (2012) The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. *Ann Intern Med* 156: 271–278. doi: [10.1059/0003-4819-156-4-201202210-00004](https://doi.org/10.1059/0003-4819-156-4-201202210-00004) PMID: [22351712](https://pubmed.ncbi.nlm.nih.gov/22351712/)
6. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS (2000) The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. *Hepatology* 31: 777–782. doi: [10.1002/hep.510310332](https://doi.org/10.1002/hep.510310332) PMID: [10706572](https://pubmed.ncbi.nlm.nih.gov/10706572/)
7. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology* 122: 1303–1313. doi: [10.1053/j.gastro.2002.03.015](https://doi.org/10.1053/j.gastro.2002.03.015) PMID: [11984517](https://pubmed.ncbi.nlm.nih.gov/11984517/)
8. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. (2013) A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. *Clin Infect Dis* 57: 230–236. doi: [10.1093/cid/cit234](https://doi.org/10.1093/cid/cit234) PMID: [23616492](https://pubmed.ncbi.nlm.nih.gov/23616492/)
9. Fretz R, Negro F, Bruggmann P, Lavanchy D, De Gottardi A, Pache I, et al. (2013) Hepatitis B and C in Switzerland—healthcare provider initiated testing for chronic hepatitis B and C infection. *Swiss Med Wkly* 143: 0. doi: [10.4414/smw.2013.13793](https://doi.org/10.4414/smw.2013.13793) PMID: [23616492](https://pubmed.ncbi.nlm.nih.gov/23616492/)
10. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. (2011) A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. *Liver Int* 31 Suppl 2: 30–60. doi: [10.1111/j.1478-3231.2011.02539.x](https://doi.org/10.1111/j.1478-3231.2011.02539.x) PMID: [21651702](https://pubmed.ncbi.nlm.nih.gov/21651702/)
11. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. (2014) The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. *J Viral Hepat* 21 Suppl 1: 34–59. doi: [10.1111/jvh.12248](https://doi.org/10.1111/jvh.12248) PMID: [24713005](https://pubmed.ncbi.nlm.nih.gov/24713005/)
12. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. (2014) Historical epidemiology of hepatitis C virus (HCV) in selected countries. *J Viral Hepat* 21 Suppl 1: 5–33. doi: [10.1111/jvh.12247](https://doi.org/10.1111/jvh.12247) PMID: [24713004](https://pubmed.ncbi.nlm.nih.gov/24713004/)
13. Sagmeister M, Renner EL, Mullhaupt B, Wong JB (2002) Simulation of hepatitis C based on a mandatory reporting system. *Eur J Gastroenterol Hepatol* 14: 25–34. PMID: [11782572](https://pubmed.ncbi.nlm.nih.gov/11782572/)
14. Swiss Federal Office of Public Health (2013) Number of hepatitis C cases reported in Switzerland between 1988 and 2012 by year of birth (mandatory notification of laboratory confirmed cases): FOPH/ID/EPI/RIC.
15. The Swiss Hepatitis C Cohort Study (2014) Study Population; Some salient features. [cites April 15 2014] Available: <http://www.swisshcv.ch/study-population.htm>.
16. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Ann Intern Med* 144: 705–714. doi: [10.1093/ajcp/144/10/705](https://doi.org/10.1093/ajcp/144/10/705) PMID: [16702586](https://pubmed.ncbi.nlm.nih.gov/16702586/)
17. United Nations Department of Economic and Social Affairs Population Division (2011) World population prospects: The 2010 revision. Population database. [cited:Feb 1 2013]. Available: <http://esa.un.org/unpd/wpp/index.htm>.
18. Swiss Federal Office of Public Health (2013) Number of acute cases of hepatitis C in Switzerland by reporting year: FOPH/ID/EPI/RIC.

19. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. *Hepatology* 57: 1333–1342. doi: [10.1002/hep.26141](https://doi.org/10.1002/hep.26141) PMID: [23172780](https://pubmed.ncbi.nlm.nih.gov/23172780/)
20. Swiss Federal Statistics Office (2011) Permanent foreign resident population by nationality by country and Canton, 1990–2010. su-f-1.3.1.1.23. Available: <http://www.bfs.admin.ch/bfs>.
21. University of California B, Max Planck Institute for Demographic Research (2013) Human Mortality Database. Jun 14 2013 [cited:Feb 1 2013]. Available: www.mortality.org.
22. Swiss Federal Statistics Office (2013) Fatalities by institutional divisions, gender, nationality, marital status and age group, 1971–2010. STAT-TAB: The interactive statistical database. [cited:Jun 17 2013] Available: <http://www.pxweb.bfs.admin.ch/Dialog/statfile.asp?lang=1>.
23. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M (2013) Mortality among people who inject drugs: a systematic review and meta-analysis. *Bull World Health Organ* 91: 102–123. doi: [10.2471/BLT.12.108282](https://doi.org/10.2471/BLT.12.108282); BLT.12.108282 [pii]. PMID: [23554523](https://pubmed.ncbi.nlm.nih.gov/23554523/)
24. Degenhardt L, Hall W, Warner-Smith M (2006) Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. *Sex Transm Infect* 82 Suppl 3: iii56–iii63. 82/suppl_3/iii56 [pii]; doi: [10.1136/sti.2005.019273](https://doi.org/10.1136/sti.2005.019273) PMID: [16735295](https://pubmed.ncbi.nlm.nih.gov/16735295/)
25. Hickman M, Hope V, Coleman B, Parry J, Telfer M, Twigger J, et al. (2009) Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. *J Public Health (Oxf)* 31: 374–382. fdp067 [pii]; doi: [10.1093/pubmed/fdp067](https://doi.org/10.1093/pubmed/fdp067) PMID: [19596666](https://pubmed.ncbi.nlm.nih.gov/19596666/)
26. Nordt C, Stohler R (2010) Combined effects of law enforcement and substitution treatment on heroin mortality. *Drug Alcohol Rev* 29: 540–545. DAR167 [pii]; doi: [10.1111/j.1465-3362.2009.00167.x](https://doi.org/10.1111/j.1465-3362.2009.00167.x) PMID: [20887578](https://pubmed.ncbi.nlm.nih.gov/20887578/)
27. Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F (2007) Cohort profile: The Swiss hepatitis C cohort study (SCCS). *Int J Epidemiol* 36: 731–737. dym096 [pii]; doi: [10.1093/ije/dym096](https://doi.org/10.1093/ije/dym096) PMID: [17693458](https://pubmed.ncbi.nlm.nih.gov/17693458/)
28. Dubois-Arber F, Balthasar H, Huissoud T, Zobel F, Arnaud S, Samitca S, et al. (2008) Trends in drug consumption and risk of transmission of HIV and hepatitis C virus among injecting drug users in Switzerland, 1993–2006. *Euro Surveill* 13.
29. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. (2013) Chronic hepatitis C virus (HCV) disease burden and cost in the United States. *Hepatology* 57: 2164–2170. doi: [10.1002/hep.26218](https://doi.org/10.1002/hep.26218) PMID: [23280550](https://pubmed.ncbi.nlm.nih.gov/23280550/)
30. IMS Health (2013) IMS Health MIDAS Data. IMS Health. Jan 1 2013 Available: <http://www.imshealth.com/portal/site/ims/menuitem.edb2b81823f67dab41d84b903208c22a/?vgnextoid=4475e3de7e390310VgnVCM1000007f8c2ca2RCRD>.
31. Evon DM, Verma A, Dougherty KA, Batey B, Russo M, Zacks S, et al. (2007) High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. *Dig Dis Sci* 52: 3251–3258. doi: [10.1007/s10620-006-9669-0](https://doi.org/10.1007/s10620-006-9669-0) PMID: [17394072](https://pubmed.ncbi.nlm.nih.gov/17394072/)
32. Morrill JA, Shrestha M, Grant RW (2005) Barriers to the treatment of hepatitis C. Patient, provider, and system factors. *J Gen Intern Med* 20: 754–758. JGI05307 [pii]; doi: [10.1111/j.1525-1497.2005.0161.x](https://doi.org/10.1111/j.1525-1497.2005.0161.x) PMID: [16050887](https://pubmed.ncbi.nlm.nih.gov/16050887/)
33. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. (2011) Outcomes of treatment for hepatitis C virus infection by primary care providers. *N Engl J Med* 364: 2199–2207. doi: [10.1056/NEJMoa1009370](https://doi.org/10.1056/NEJMoa1009370) PMID: [21631316](https://pubmed.ncbi.nlm.nih.gov/21631316/)
34. World Health Organization (2008) Task Shifting: Global Recommendations and Guidelines. 1–95.
35. Mdege ND, Chindove S, Ali S (2013) The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review. *Health Policy Plan* 28: 223–236. czs058 [pii]; doi: [10.1093/heapol/czs058](https://doi.org/10.1093/heapol/czs058) PMID: [22738755](https://pubmed.ncbi.nlm.nih.gov/22738755/)
36. Aronsohn A, Jensen D (2014) Expanding access to hepatitis C virus care: a call to deconstruct individualized therapy. *Hepatology* 59: 13–15. doi: [10.1002/hep.26590](https://doi.org/10.1002/hep.26590) PMID: [23788009](https://pubmed.ncbi.nlm.nih.gov/23788009/)
37. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. (2012) Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. *MMWR Recomm Rep* 61: 1–32. rr6104a1 [pii]. PMID: [23135062](https://pubmed.ncbi.nlm.nih.gov/23135062/)